Seres Therapeutics, Inc. (MCRB)

Seres Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	136.15	171.22	188	116.05	65.13
Short-Term Investments	0	18.31	110.7	137.57	29.69
Cash & Cash Equivalents	136.15	189.53	298.71	253.62	94.82
Cash Growth	-28.16%	-36.55%	17.78%	167.48%	10.34%
Receivables	8.67	0	0	9.39	1.79
Inventory	29.65	0	0	0	0
Other Current Assets	0.94	5.24	4.92	5.77	3.59
Total Current Assets	175.41	194.76	303.63	268.78	100.19
Property, Plant & Equipment	132.25	133.97	36.15	22.94	30.85
Long-Term Investments	1.4	1.4	1.9	51.23	1.4
Other Long-Term Assets	49.54	18.65	13.19	0	0
Total Long-Term Assets	183.19	154.02	51.23	74.16	32.25
Total Assets	358.6	348.78	354.86	342.94	132.44
Accounts Payable	3.64	17.44	13.74	4.02	4.86
Deferred Revenue	103.09	96.69	103.82	108.17	119.74
Current Debt	6.68	4.06	6.61	5.57	4.46
Other Current Liabilities	-14.75	-32.59	-41.9	-71.35	-83.06
Total Current Liabilities	98.66	85.6	82.26	46.42	45.99
Long-Term Debt	207.26	158.53	42.6	35.2	40.32
Other Long-Term Liabilities	97.54	93.87	98.49	86.58	94.45
Total Long-Term Liabilities	304.8	252.41	141.09	121.78	134.77
Total Liabilities	403.46	338	223.35	168.19	180.76
Total Debt	213.94	162.59	49.21	40.77	44.78
Debt Growth	31.58%	230.39%	20.71%	-8.96%	-
Retained Earnings	-978.24	-864.51	-614.35	-548.78	-459.65
Comprehensive Income	0	-0.01	-0.06	-0.05	0
Shareholders' Equity	-44.86	10.78	131.51	174.75	-48.32
Net Cash / Debt	-77.79	26.94	249.5	212.85	50.04
Net Cash / Debt Growth	-	-89.20%	17.22%	325.39%	-41.77%
Net Cash Per Share	-0.61	0.25	2.72	2.67	0.88
Working Capital	76.75	109.17	221.37	222.36	54.2
Book Value Per Share	-0.35	0.10	1.43	2.19	-0.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).